Benjamin Hickey Biography and Net Worth

President, RayzeBio of Bristol Myers Squibb

Ben Hickey, president, RayzeBio, is responsible for the leadership of RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb which operates as a stand-alone entity, focused on the advancement of radiopharmaceuticals. In his role, Ben is responsible for the strategic growth of RayzeBio’s differentiated actinium-based radiopharmaceutical platform to enable rapid development of programs and therapies for the benefit of patients around the world.

“I have seen first-hand the impact Bristol Myers Squibb therapies have had on the lives of my immediate and extended family members; this patient impact is ingrained in all we do. Cutting edge innovation, like radiopharmaceutical technology, helps us to expand our reach and deliver on our mission to help patients.”

With over 20 years of industry experience, Ben joined BMS in 2024 following the acquisition of Mirati Therapeutics where he was most recently chief commercial officer and head of Business Development. Prior to Mirati, Ben was senior vice president, chief commercial officer at Halozyme Therapeutics, where he was responsible for the global commercial strategy for the company’s oncology portfolio.

Previously, Ben spent 17 years at Bristol Myers Squibb in various roles, including general manager, UK & Ireland, where he oversaw an organization of more than 300 people, and vice president Marketing, Immuno-Oncology.

Ben received both his MBA and B.S. in management from St. John’s University in Queens, New York.

What is Benjamin Hickey's net worth?: The estimated net worth of Benjamin Hickey is at least $457.21 thousand as of May 9th, 2025. Mr. Hickey owns 8,789 shares of Bristol Myers Squibb stock worth more than $457,213 as of December 4th. This net worth approximation does not reflect any other investments that Mr. Hickey may own. Learn More about Benjamin Hickey's net worth.
How do I contact Benjamin Hickey?: The corporate mailing address for Mr. Hickey and other Bristol Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Benjamin Hickey's contact information.
Has Benjamin Hickey been buying or selling shares of Bristol Myers Squibb?: Benjamin Hickey has not been actively trading shares of Bristol Myers Squibb during the last quarter. Most recently, Benjamin Hickey sold 97 shares of the business's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $38.01, for a transaction totalling $3,686.97. Following the completion of the sale, the insider now directly owns 8,789 shares of the company's stock, valued at $334,069.89. Learn More on Benjamin Hickey's trading history.
Who are Bristol Myers Squibb's active insiders?: Bristol Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Benjamin Hickey (President, RayzeBio), Samit Hirawat (EVP, Chief Medical Officer and Head of Development), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Wendy Short Bartie (Executive Vice President, Corporate Affairs), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol Myers Squibb?: During the last year, Bristol Myers Squibb insiders bought shares 2 times. They purchased a total of 6,073 shares worth more than $302,188.32. During the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 56,475 shares worth more than $2,670,885.91. The most recent insider tranaction occured on September, 2nd when EVP David V Elkins sold 56,000 shares worth more than $2,650,480.00. Insiders at Bristol Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol Myers Squibb.
Information on this page was last updated on 9/2/2025.

Benjamin Hickey Insider Trading History at Bristol Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/9/2025	Sell	97	$38.01	$3,686.97	8,789

Benjamin Hickey Buying and Selling Activity at Bristol Myers Squibb

Bristol Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $52.02

$50.23

$52.08

50 Day Range

MA: $46.05

$42.62

$52.02

2 Week Range

Now: $52.02

$42.52

$63.33

Volume

20,467,318 shs

Average Volume

13,734,128 shs

Market Capitalization

$105.90 billion

P/E Ratio

17.57

Dividend Yield

4.87%

Beta

0.29